3D-Pharmacophore Models for Selective A2A and A2B Adenosine Receptor Antagonists
暂无分享,去创建一个
Jing Wei | Songqing Wang | Qingzhi Gao | Shaofen Gao | Xuedong Dai | Qingzhi Gao | Jing Wei | X. Dai | Songqing Wang | Shaofen Gao
[1] S. Moro,et al. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation. , 2003, Journal of medicinal chemistry.
[2] E. Israel,et al. Treatment of asthma with drugs modifying the leukotriene pathway. , 1999, The New England journal of medicine.
[3] K. Jacobson,et al. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.
[4] C. Müller,et al. Development of spin-labeled probes for adenosine receptors. , 2005, Journal of medicinal chemistry.
[5] H. V. van Vlijmen,et al. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists. , 2004, Journal of medicinal chemistry.
[6] Andrew Smellie,et al. Poling: Promoting conformational variation , 1995, J. Comput. Chem..
[7] J. Lipsky,et al. Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. , 1998, Mayo Clinic proceedings.
[8] G. Burnstock,et al. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells , 1996, Trends in Neurosciences.
[9] Giovanni Piersanti,et al. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. , 2005, Journal of medicinal chemistry.
[10] B. Fredholm,et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.
[11] Irini A. Doytchinova,et al. CoMFA Study on Adenosine A2A Receptor Agonists , 2001 .
[12] C. Müller,et al. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.
[13] J. Downey,et al. Adenosine-induced vasodilation: receptor characterization in pulmonary circulation. , 1995, The American journal of physiology.
[14] Y. Kurogi,et al. 1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands. , 2002, Journal of medicinal chemistry.
[15] S. Hourani,et al. Role of cyclic nucleotides in vasodilations of the rat thoracic aorta induced by adenosine analogues , 2001, British journal of pharmacology.
[16] G. Spalluto,et al. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. , 2002, Journal of medicinal chemistry.
[17] B. Neustadt,et al. The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists. , 2005, Bioorganic & medicinal chemistry letters.
[18] J. Grider,et al. Adenosine A1 and A2b receptors coupled to distinct interactive signaling pathways in intestinal muscle cells. , 1995, The Journal of pharmacology and experimental therapeutics.
[19] K. Varani,et al. Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] A. Ivanov,et al. Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists. , 2005, Journal of Medicinal Chemistry.
[21] R. Howell,et al. Mechanism for the emetic side effect of xanthine bronchodilators. , 1990, Life sciences.
[22] S. Moro,et al. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen. , 2000, Journal of medicinal chemistry.
[23] I. Biaggioni,et al. Adenosine-Activated Mast Cells Induce IgE Synthesis by B Lymphocytes: An A2B-Mediated Process Involving Th2 Cytokines IL-4 and IL-13 with Implications for Asthma12 , 2004, The Journal of Immunology.
[24] E. Jackson,et al. Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. , 1998, Hypertension.
[25] K. Klotz,et al. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. , 2000, Journal of medicinal chemistry.
[26] Jan Balzarini,et al. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. , 2005, Journal of medicinal chemistry.
[27] T. Engber,et al. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists. , 2004, Bioorganic & medicinal chemistry letters.
[28] K. Varani,et al. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. , 2004, Journal of medicinal chemistry.
[29] K. Jacobson,et al. 1,3‐dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors , 1999, Drug development research.
[30] K. Jacobson,et al. Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. , 2002, Journal of medicinal chemistry.
[31] E. Ongini,et al. Adenosine A2A Receptors and Neuroprotection , 1997, Annals of the New York Academy of Sciences.
[32] K. Jacobson,et al. P1 and P2 Purine and Pyrimidine Receptor Ligands , 2001 .
[33] I. Feoktistov. Adenosine A 2 B Receptors , 1998 .
[34] K. Jacobson,et al. Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor. , 1994, European journal of pharmacology.
[35] H. Kase,et al. Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. , 1993, Journal of medicinal chemistry.
[36] D. Zeng,et al. The discovery of a selective, high affinity A(2B) adenosine receptor antagonist for the potential treatment of asthma. , 2005, Bioorganic & medicinal chemistry letters.
[37] Thea Mulder-Krieger,et al. 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. , 2004, Journal of medicinal chemistry.
[38] K. Klotz,et al. 8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists. , 1998, Bioorganic & medicinal chemistry.
[39] P. Jenner,et al. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. , 1997, Trends in pharmacological sciences.
[40] G. Chrousos,et al. Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications. , 2000, Annals of the New York Academy of Sciences.
[41] K. Varani,et al. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. , 2005, Journal of medicinal chemistry.
[42] K. Jacobson,et al. Acyl‐hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors , 1999 .
[43] K. Varani,et al. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists. , 2005, Journal of medicinal chemistry.